Early Chronic Bronchitis MEDICAL JOURNAL nor therapy had any effect on the rate of decline of F.E.V. or on the volume or purulence of sputum specimens.We wish to record our appreciation to Pfizer Limited for their generous supply of oxytetracycline and indistinguishable dummy tablets, and for their willing cooperation in the analysis of numerous blood and urine samples for oxytetracycline, both before and during the trial ; and to Messrs. Parke Davis and Co. for their supply of chloramphenicol, sulphamethoxypyridazine, and penicillin capsules. Murphy (1963), and by the fact that three of our own severe but fortunately non-fatal cases were also doctors' wives in whom there was considerable delay in diagnosis. This failure is mirrored in a number of otherwise excellent monographs and conference proceedings on the pulmonary circulation, and even one on pulmonary embolic disease, which have nothing whatever to say on fatal pulmonary embolism in healthy persons.The frequency with which we made this clinical diagnosis led us to wonder if there were not a number of such patients who died either before diagnosis was made or before treatment could be effectively instituted (Fleming, 1962). This led to the present study of fatal cases, and of cases diagnosed and treated in life.* Consultant Cardiologist, East Anglian Regional Hospi:al Board and Addenbrooke's Hospital, Cambridge. Of the nine cases of sudden death outside hospital eight were women, and all but one had a recorded complaint of some dyspnoea or chest discomfort preceding death. The 23-year-old patient was five months pregnant, and had been treated for venous thrombosis three and a half weeks previously.In all cases either a large embolus straddled the pulmonary artery bifurcation or both main pulmonary arteries were blocked
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.